Mitochondrial Myopathies: Clinical Trials

4 trials for Mitochondrial Myopathies, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 1 recruiting, 1 terminated. 4 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 34Completed 2, Recruiting 1, Terminated 1
Phase 21Terminated 1

Follow Mitochondrial Myopathies: new trials by email Literature Review of Mitochondrial Myopathies trials Research Report on Mitochondrial Myopathies

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
KHENERFIN Study: A Trial to Evaluate the Efficacy and Safety of Sonlicromanol in Primary Mitochondrial Diseases
Sonlicromanol, Placebo - Mitochondrial Diseases, Maternally Inherited Diabetes and Deafness (MIDD)
Phase 3RecruitingKhondrion BV2202026-04-142026-10-14
A Safety Study for Previously Treated Vatiquinone (PTC743) Participants With Inherited Mitochondrial Disease
Vatiquinone - Inherited Mitochondrial Disease
Phase 3CompletedPTC Therapeutics1012022-06-222025-12-22
Study to Evaluate Efficacy and Safety of Elamipretide in Subjects With Primary Mitochondrial Disease From Nuclear DNA Mutations (nPMD)
Elamipretide, Placebo - Mitochondrial Myopathies, Mitochondrial Pathology
Phase 3CompletedStealth BioTherapeutics Inc.1022022-04-292025-10-24
A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy
Vatiquinone, Placebo - Mitochondrial Diseases, Drug Resistant Epilepsy
Phase 2 / Phase 3TerminatedPTC Therapeutics682020-09-282026-03-31

Narrower conditions

MELAS Syndrome (3)  ·  Mitochondrial Diseases (3)  ·  Diffuse Cerebral Sclerosis of Schilder (2)  ·  Drug Resistant Epilepsy (2)  ·  Leigh Disease (2)  ·  MERRF Syndrome (2)  ·  Mitochondrial Encephalomyopathies (1)  ·  Mitochondrial complex I deficiency (1)  ·  Mitochondrial encephalopathy (1)  ·  Muscle Weakness (1)  ·  Nerve Degeneration (1)  ·  Noninsulin-dependent diabetes mellitus with deafness (1)  ·  Ophthalmoplegia, Chronic Progressive External (1)  ·  Pontocerebellar Hypoplasia Type 6 (1)

Broader conditions

Metabolic Diseases (4)  ·  Muscular Diseases (4)  ·  Musculoskeletal Diseases (4)  ·  Nervous System Diseases (4)  ·  Neuromuscular Diseases (4)  ·  Nutritional and Metabolic Diseases (4)  ·  Brain Diseases (3)  ·  Brain Diseases, Metabolic (3)  ·  Brain Diseases, Metabolic, Inborn (3)  ·  Cardiovascular Diseases (3)  ·  Central Nervous System Diseases (3)  ·  Cerebral Small Vessel Diseases (3)  ·  Cerebrovascular Disorders (3)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3)  ·  Genetic Diseases, Inborn (3)

Interventions

alpha-tocotrienol quinone (2)  ·  arginyl-2,'6'-dimethyltyrosyl-lysyl-phenylalaninamide (1)

Sponsors

PTC Therapeutics (2)  ·  Khondrion BV (1)  ·  Stealth BioTherapeutics Inc. (1)

Countries

Italy (4)  ·  United Kingdom (4)  ·  United States (4)  ·  France (3)  ·  Spain (3)  ·  Germany (2)  ·  Japan (2)  ·  Netherlands (2)  ·  Poland (2)  ·  Australia (1)  ·  Canada (1)  ·  Denmark (1)  ·  Hungary (1)  ·  New Zealand (1)  ·  Norway (1)

Top investigators

Vinay Penematsa, MD (2)